ObjectiveTo analyze the epidemiological characteristics and antimicrobial resistance of clinically isolated Pseudomonas putida(P. putida), and provide basis for rational prevention and treatment of P. putida infection. MethodsP. putida isolated between January 2010 and December 2015, as well as clinical data of patients infected with P. putida were collected, antimicrobial susceptibility of isolates was determined by KirbyBauer disk diffusion susceptibility testing of Clinical and Laboratory Standards Institute (CLSI) of America, susceptibility testing results of isolated strains were analyzed by WHONET 5.5 software.  ResultsA total of 91 strains of P. putida were isolated from clinical specimens, most were from elderly patients aged >60 years(70.33%); the major underlying disease was communityacquired pneumonia (23.08%)，followed by chronic pulmonary heart disease(15.38%); the main specimen was sputum(57.14%), followed by urine(27.47%); P. putida mainly distributed in department of respiratory medicine (28.57%), followed by department of cardiovascular medicine (13.19%). P. putida had high resistance rate to aztreonam (52.75%), while resistance rates to gentamicin, imipenem, levofloxacin, ceftazidime, meropenem, and ciprofloxacin were 7.78%, 9.89%, 2.20%, 9.89%, 7.69%, and 2.22% respectively, resistance rates to amikacin and polymyxin were both 0. ConclusionP. putida infection mainly occurs in elderly patients with underlying diseases, mainly respiratory tract infection, resistance rates to most antimicrobial agents were <10%.